David Nierengarten

Myokardia Analysts See Mavacamten As Blockbuster Opportunity For Bristol-Myers Squibb

Wedbush Starts Iveric Bio Coverage With Bullish Rating On Zimura's Upcoming Pivotal Study

Wedbush: Investors Largely Underappreciating AnaptysBio

Wedbush Starts Iveric Bio Coverage With Bullish Rating On Zimura's Upcoming Pivotal Study

Wedbush: Investors Largely Underappreciating AnaptysBio

Wedbush: Y-mAbs Could Attract Investor Attention As Market Volatility Grows

Bluebird Bio's Near-Term Product Launches Pose Risks, Wedbush Says In Downgrade

Wedbush: Y-mAbs Could Attract Investor Attention As Market Volatility Grows

Bluebird Bio's Near-Term Product Launches Pose Risks, Wedbush Says In Downgrade

Wedbush: Trajectory For Stemline Therapeutics' Blood Cancer Drug Priced Into Stock

FDA Delays Selinexor Approval By 3 Months — So Why Is Karyopharm Ripping Higher?

David Nierengarten Recent News

Analysts Slash KaryoPharm Price Targets By Over 50% After Adcom Setback

Sell-Side Roundup: What's Next For For Applied Genetic After 50% Plunge?

Wedbush Moves To The Sidelines On Tesaro Following Glaxo Deal

Wedbush Bets On Magenta Therapeutics, Projects Rewards If Stem Cell Technology Successful

'We Expect A Quick Resolution': Despite Partial Clinical Hold On Epizyme's Drug Candidate, Wedbush Stays Bullish

Analyst: Spark Therapeutics' $850K Blindness Drug Has Smaller-Than-Expected Market

Wedbush Rates Kura Oncology Outperform As Catalysts Loom

Endocyte Shares Up More Than 100% In 2 Days, But Analyst Sees Even More Upside Possible

A Data-Rich Year Has Analysts Accepting Their Fate Therapeutics Trade

Wedbush Cuts TESARO Target By 18% Following SOLO-2 Results

Wedbush Asks: How Does Kite Pharma's ZUMA-1 Compare To Juno's TRANSCEND?

Bluebird Bio Shares Could See Value Fly To $95 As 2017 Will Be A 'Catalyst-Filled Year'

Analyst Breaks Down Bluebird Bio's Better-Than-Expected Clinical Results

Good And Bad News from Epizyme; Wedbush Analyst Weighs In

Tailwinds Continue To Hold The Street's Gaze Toward Bluebird Bio Aloft

Wedbush Raises TESARO Price Target From $107 To $139

Audentes Therapeutics Initiated Overweight At Wedbush

Bluebuird Bio Crashes Nearly 30%: What's Next?

How Wedbush Sees The Alexion–Synageva Deal